Mechanisms leading to in vivo ceftolozane/tazobactam resistance development in Pseudomonas aeruginosa

REIPI researchers, led by H. Son Espases Group, Have characterized the mechanisms driving resistance development to the new antipseudomonal combination ceftolozane/tazobactam in 5 patients treated for MDR Pseudomonas aeruginosa infections. In all five cases, the same clone was detected for the susceptible/resistant pairs; the widespread ST175 high-risk clone in four of the cases and ST179 in the…